Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20 months after their last dose (at about 3.5 years of...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Canadian Medical Association
2015
|
| _version_ | 1797091284765114368 |
|---|---|
| author | McQuaid, F Snape, M John, T Kelly, S Robinson, H Yu, L Toneatto, D D'Agostino, D Dull, P Pollard, A |
| author_facet | McQuaid, F Snape, M John, T Kelly, S Robinson, H Yu, L Toneatto, D D'Agostino, D Dull, P Pollard, A |
| author_sort | McQuaid, F |
| collection | OXFORD |
| description | BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20 months after their last dose (at about 3.5 years of age). METHODS: We assessed 5-year-old children who received the 4CMenB vaccine or a recombinant protein vaccine in a previous randomized trial. We also recruited 50 vaccine-naive 5-year-olds and administered 2 doses of 4CMenB to each child. We measured serum bactericidal antibody titres against 4 indicator strains of serogroup B meningococcus matched to each individual vaccine component and against 4 mismatched strains. RESULTS: Of those who received the 4CMenB vaccine at 2, 4, 6, 12 and 40 months (n = 16), the percentage with protective antibody titres (≥ 1:4) at 60 months ranged from 44% to 88% against matched strains and from 13% to 81% against mismatched strains. Loss of protective titres was also observed for those who received the 4CMenB vaccine at 12, 40 and 42 months (n = 5) (80%-100% against matched strains, 60%-100% against mismatched strains) or at 40 and 42 months (n = 29) (31%-100% against matched strains, 41%-81% against mismatched strains). Administering the 4CMenB vaccine to 5-year-old children yielded protective titres against matched strains in 92%-100% and against mismatched strains in 59%-100%. The majority of these children reported injection-site pain (40/50 [80%] after dose 1, 39/46 [85%] after dose 2) and erythema (47/50 [94%] and 40/46 [87%], respectively); rates of fever were low (5/50 [10%] and 2/46 [4%], respectively). INTERPRETATION: Waning of immunity by 5 years of age occurred after receipt of the 4CMenB vaccine in infancy, even with an additional booster at 40 months. The 4CMenB vaccine is immunogenic and was fairly well tolerated by 5-year-old children, although injection-site pain was noteworthy. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01027351. |
| first_indexed | 2024-03-07T03:30:46Z |
| format | Journal article |
| id | oxford-uuid:baa3ee04-60b4-4852-8ce9-e5d47ceb9b30 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:30:46Z |
| publishDate | 2015 |
| publisher | Canadian Medical Association |
| record_format | dspace |
| spelling | oxford-uuid:baa3ee04-60b4-4852-8ce9-e5d47ceb9b302022-03-27T05:11:15ZPersistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:baa3ee04-60b4-4852-8ce9-e5d47ceb9b30EnglishSymplectic Elements at OxfordCanadian Medical Association2015McQuaid, FSnape, MJohn, TKelly, SRobinson, HYu, LToneatto, DD'Agostino, DDull, PPollard, ABACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20 months after their last dose (at about 3.5 years of age). METHODS: We assessed 5-year-old children who received the 4CMenB vaccine or a recombinant protein vaccine in a previous randomized trial. We also recruited 50 vaccine-naive 5-year-olds and administered 2 doses of 4CMenB to each child. We measured serum bactericidal antibody titres against 4 indicator strains of serogroup B meningococcus matched to each individual vaccine component and against 4 mismatched strains. RESULTS: Of those who received the 4CMenB vaccine at 2, 4, 6, 12 and 40 months (n = 16), the percentage with protective antibody titres (≥ 1:4) at 60 months ranged from 44% to 88% against matched strains and from 13% to 81% against mismatched strains. Loss of protective titres was also observed for those who received the 4CMenB vaccine at 12, 40 and 42 months (n = 5) (80%-100% against matched strains, 60%-100% against mismatched strains) or at 40 and 42 months (n = 29) (31%-100% against matched strains, 41%-81% against mismatched strains). Administering the 4CMenB vaccine to 5-year-old children yielded protective titres against matched strains in 92%-100% and against mismatched strains in 59%-100%. The majority of these children reported injection-site pain (40/50 [80%] after dose 1, 39/46 [85%] after dose 2) and erythema (47/50 [94%] and 40/46 [87%], respectively); rates of fever were low (5/50 [10%] and 2/46 [4%], respectively). INTERPRETATION: Waning of immunity by 5 years of age occurred after receipt of the 4CMenB vaccine in infancy, even with an additional booster at 40 months. The 4CMenB vaccine is immunogenic and was fairly well tolerated by 5-year-old children, although injection-site pain was noteworthy. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01027351. |
| spellingShingle | McQuaid, F Snape, M John, T Kelly, S Robinson, H Yu, L Toneatto, D D'Agostino, D Dull, P Pollard, A Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title | Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title_full | Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title_fullStr | Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title_full_unstemmed | Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title_short | Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. |
| title_sort | persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup b meningococcus in infancy and at 40 months |
| work_keys_str_mv | AT mcquaidf persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT snapem persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT johnt persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT kellys persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT robinsonh persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT yul persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT toneattod persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT dagostinod persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT dullp persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months AT pollarda persistenceofspecificbactericidalantibodiesat5yearsofageaftervaccinationagainstserogroupbmeningococcusininfancyandat40months |